The adage 'do more with less' is of increasing relevance to global economies, with governments under pressure to cut and compress public spend yet simultaneously increase both productivity and
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.
